MMP2 and chronic myelogenous leukemia, BCR-ABL1 positive: Tunicamycin, which was proven in our experiments to diminish CD147 glycosylation, also suppressed the increases in MMP2/9 expression and activity in response to HG and CML (Figure 6A–D) confirming the role of the glycosylated CD147 in MMP induction.